Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.

Yu Liu,Wen-Zhu Wan,Yan Li,Guan-Lian Zhou,Xin-Guang Liu
DOI: https://doi.org/10.18632/oncotarget.12742
2017-01-01
Oncotarget
Abstract:Phosphatidylinostitol-3-kinase (PI3K) is the potential anticancer target in the PI3K/Akt/mTOR pathway. Here we reviewed the ATP-competitive small molecule PI3K inhibitors in the past few years, including the pan Class I PI3K inhibitors, the isoform-specific PI3K inhibitors and/or the PI3K/mTOR dual inhibitors.
What problem does this paper attempt to address?